Drug intelligence / Profile preview

Tianqi Pingchan Granule

Development stage: Unknown
Lead developer: Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

Tianqi Pingchan Granule (TPG) is a compound traditional Chinese herbal medicine developed for treating Parkinson's disease (PD) and its complications, particularly levodopa-induced dyskinesia (LID). It has been used in combination with conventional treatments like amantadine to effectively reduce dyskinesia symptoms in PD patients undergoing long-term levodopa therapy. Clinical trials have demonstrated its efficacy in reducing Unified Dyskinesia Rating Scale (UDysRS) scores with good tolerability.

Brand names: Tianqi Pingchan Granule
Other names: TPG

Targets

GRK6 (G protein-coupled receptor kinase 6)IL-6 (Interleukin 6)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on Tianqi Pingchan Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianqi Pingchan Granule.

Explore the full profile